| abstract |
The present invention generally has 5-HT6 receptor affinity and has the formula (I) wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein. Or an individual isomer thereof, a racemic or non-racemic mixture of isomers, or a pharmaceutically acceptable salt or solvate. The invention further relates to pharmaceutical compositions comprising such compounds, methods for their use as therapeutic agents, and methods for their production. |